What is DSIP?
DSIP appears in FDA's safety table as Emideltide (DSIP). The agency's July 2026 briefing describes emideltide as a nine-amino-acid peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. This connects the abbreviation to an evaluated substance; the sleep-related name does not itself establish a sleep benefit. FDA compounding safety communication, FDA emideltide assessment.
The DSIP vial listing shows 5mg / 10mg as separate catalogue variants. These amounts identify presentations, rather than a concentration or an amount to administer. The named peptide and the listed variants answer identity questions; the clinical evidence asks a different question about measured sleep outcomes. FDA emideltide assessment.
The 16-patient insomnia study
A 1992 double-blind study enrolled 16 patients with chronic insomnia. It used polysomnography and subjective ratings as separate assessments. DSIP insomnia study.
The investigators judged the statistically significant objective effects weak and potentially partly attributable to an incidental change in the placebo group. Subjective sleep quality did not change. DSIP insomnia study.
This was a small study in people with chronic insomnia. Its objective measurements cannot be collapsed into a broad claim that DSIP reliably improves sleep, and its findings do not validate this supplier vial. DSIP insomnia study.
Compounding safety concerns
FDA identifies potential immune-response and peptide-characterization concerns for compounded emideltide. These concerns apply to the compounded substance discussed in its communication. The emideltide definition does not resolve them, and the DSIP name alone does not authenticate a supplier formulation. FDA compounding safety communication.
The DSIP pen is a separate presentation with 5mg / 10mg catalogue variants. Matching amount options do not establish matching formulation or clinical performance.
